I love paxalisib, evt801 has real potential. You need to keep everyone aligned with how trials are progressing. The fallacy that is spread around 'it's great that they aren't reporting on time, as patients are living longer' is just that; a fallacy! Look at the primary and secondary outcome milestones on clinicaltrials.org, once a patient meets the 6 month milestone of dfp the patient data can be reported. If they live dfp longer that is amazing and quite probably happening. I think the drugs have real potential, having lost loved ones to cancer I want to see drugs were they need to be. Management 101: under promise over deliver! DIPG data that was promised by Dr. Friend in July then Aug, then Sept and all we get is an abstract with no data...does anyone want to put potential life saving drugs in the hands of this team???
- Forums
- ASX - By Stock
- KZA
- Ann: Acceptance of late-breaking abstract of PNOC022 data
Ann: Acceptance of late-breaking abstract of PNOC022 data, page-5
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online